CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 6928 result(s)

Use of Real-World Evidence in Single Drug Technology Assessment Processes by Health Technology Assessment and Regulatory Organizations

Last Updated: April 18, 2018
Result type: Reports
Product Line: Environmental Scans

Traditionally, regulatory and health technology assessment organizations rely on evidence derived from randomized controlled trials (RCTs) for the assessment of new drugs. However, patients enrolled in RCTs tend to be highly selected and may not reflect the more diversified population in whom the drug may be used. Long-term effects of drugs are ...

  • Project Number: ES0323-000

letermovir (Prevymis)

Last Updated: July 9, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: letermovir
Indications: Cytomegalovirus infection, prophylaxis

  • Brand Name: Prevymis
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0545-000
  • Project Status: Complete
  • Submission Type: New